Q2 Earnings Forecast for Cingulate Issued By Zacks Research

Cingulate Inc. (NASDAQ:CING) – Research analysts at Zacks Research issued their Q2 2026 earnings per share (EPS) estimates for Cingulate in a research report issued on Tuesday, May 19th. Zacks Research analyst J. Vandermosten expects that the company will post earnings per share of ($0.59) for the quarter. The consensus estimate for Cingulate’s current full-year earnings is ($1.88) per share. Zacks Research also issued estimates for Cingulate’s Q3 2026 earnings at ($0.57) EPS, Q4 2026 earnings at ($0.54) EPS and FY2028 earnings at ($1.06) EPS.

Cingulate (NASDAQ:CING) last issued its earnings results on Thursday, May 14th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.42).

CING has been the subject of several other reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Cingulate in a research report on Monday, April 20th. Wall Street Zen downgraded shares of Cingulate from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 16th. Ascendiant Capital Markets lowered their price target on Cingulate from $58.00 to $55.00 and set a “buy” rating for the company in a report on Wednesday, April 8th. Finally, Roth Mkm reissued a “buy” rating and issued a $10.00 price objective on shares of Cingulate in a research note on Tuesday. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $32.50.

Cingulate Price Performance

CING stock opened at $4.63 on Thursday. Cingulate has a 12 month low of $3.20 and a 12 month high of $11.89. The firm’s 50-day moving average is $6.11 and its 200 day moving average is $5.32. The company has a market capitalization of $61.49 million, a PE ratio of -1.09 and a beta of -0.81.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bank of America Corp DE increased its position in Cingulate by 283.1% during the 2nd quarter. Bank of America Corp DE now owns 7,501 shares of the company’s stock valued at $31,000 after purchasing an additional 5,543 shares during the period. Soltis Investment Advisors LLC bought a new stake in shares of Cingulate in the 4th quarter valued at about $43,000. XTX Topco Ltd purchased a new stake in shares of Cingulate in the 2nd quarter worth approximately $45,000. Quadrature Capital Ltd bought a new position in shares of Cingulate during the fourth quarter valued at approximately $66,000. Finally, Quantum Private Wealth LLC boosted its stake in shares of Cingulate by 140.0% during the third quarter. Quantum Private Wealth LLC now owns 24,000 shares of the company’s stock valued at $94,000 after purchasing an additional 14,000 shares in the last quarter. 41.31% of the stock is currently owned by institutional investors.

About Cingulate

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.